X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2807) 2807
Publication (159) 159
Book Chapter (48) 48
Book Review (35) 35
Book / eBook (20) 20
Magazine Article (19) 19
Newsletter (10) 10
Conference Proceeding (3) 3
Trade Publication Article (3) 3
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2416) 2416
female (1286) 1286
male (1237) 1237
index medicus (1114) 1114
dermatology (1011) 1011
middle aged (904) 904
adult (860) 860
aged (602) 602
nail diseases - drug therapy (497) 497
onychomycosis (483) 483
treatment outcome (413) 413
nails (381) 381
nail diseases - chemically induced (360) 360
onychomycosis - drug therapy (318) 318
psoriasis (302) 302
nail (287) 287
nail diseases - pathology (282) 282
adolescent (281) 281
antifungal agents - therapeutic use (274) 274
nail diseases - diagnosis (265) 265
therapy (255) 255
psoriasis - drug therapy (243) 243
diagnosis (236) 236
nails - pathology (235) 235
care and treatment (234) 234
skin (234) 234
administration, topical (233) 233
child (229) 229
antifungal agents - administration & dosage (204) 204
nail diseases - etiology (202) 202
dermatology & venereal diseases (184) 184
mycoses (183) 183
diagnosis, differential (182) 182
surgery (175) 175
terbinafine (170) 170
health aspects (169) 169
aged, 80 and over (168) 168
drug therapy (168) 168
medicine & public health (168) 168
follow-up studies (165) 165
pharmacology & pharmacy (164) 164
severity of illness index (160) 160
young adult (153) 153
nail diseases (152) 152
nails - drug effects (151) 151
prevalence (147) 147
disease (145) 145
double-blind (145) 145
animals (144) 144
onychomycosis - microbiology (138) 138
foot dermatoses - drug therapy (134) 134
management (134) 134
risk factors (132) 132
itraconazole (131) 131
orthopedics (130) 130
epidemiology (127) 127
integumentary system (124) 124
administration, oral (122) 122
nails - microbiology (121) 121
efficacy (120) 120
onychomycosis - diagnosis (120) 120
antifungal agents (118) 118
toenail onychomycosis (117) 117
medicine, general & internal (116) 116
research (115) 115
child, preschool (113) 113
time factors (112) 112
arthritis (110) 110
analysis (108) 108
nail diseases - therapy (108) 108
nail psoriasis (108) 108
antineoplastic agents - adverse effects (107) 107
rheumatology (107) 107
infections (105) 105
patients (105) 105
nails - blood supply (101) 101
skin and connective tissue diseases (101) 101
mycology (97) 97
retrospective studies (97) 97
drug therapy, combination (93) 93
oncology (93) 93
fingers & toes (91) 91
nails - metabolism (91) 91
quality of life (90) 90
bone nails (87) 87
prospective studies (87) 87
pediatrics (86) 86
cancer (85) 85
chemotherapy (85) 85
dermatologic agents - therapeutic use (82) 82
pigmentation disorders - chemically induced (80) 80
quality-of-life (78) 78
children (77) 77
fungi (76) 76
infection (76) 76
infant (75) 75
skin diseases (75) 75
prognosis (74) 74
nail diseases - complications (73) 73
naphthalenes - therapeutic use (72) 72
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2709) 2709
German (74) 74
French (56) 56
Russian (14) 14
Spanish (13) 13
Chinese (9) 9
Italian (9) 9
Japanese (9) 9
Polish (6) 6
Dutch (3) 3
Finnish (3) 3
Portuguese (3) 3
Danish (2) 2
Korean (2) 2
Arabic (1) 1
Bulgarian (1) 1
Czech (1) 1
Hebrew (1) 1
Icelandic (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 72, Issue 2, pp. 203 - 218
There has been a rapid emergence of numerous targeted agents in the oncology community in the last decade. This exciting paradigm shift in drug development... 
Vandetanib | Panitumumab | Multikinase inhibitors | Bevacizumab | Macular eruption | Pigment changes | Paronychia | Supportive oncodermatology | Drug eruption | Sunitinib | Lapatinib | Cetuximab | Gefitinib | Vascular endothelial growth factor | Pazopanib | Dasatinib | Photosensitivity | Imatinib | Mucositis | Morbilliform | Chemotherapy | Side effects | Stomatitis | Alopecia | Disturbed wound healing | Erlotinib | Sorafenib | KIT | Monoclonal antibodies | Dry skin | Nilotinib | Drug rash | Targeted therapy | erbB receptor | Toxic erythema | Papulopustular eruption | Hyperkeratotic handefoot skin reaction | Antiangiogenic agents | Platelet-derived growth factor receptor | Ranibizumab | Small molecule | Cutaneous adverse effects | Drug reaction | Epidermal growth factor receptor inhibitors | Mucocutaneous hemorrhage | Cancer treatment | Dermatologic toxicities | BCR-ABL | Xerosis | Canertinib | Tyrosine kinase inhibitors | Dual kinase inhibitors | Adverse sequelae | Genital rash | Anticancer | HER2 | cancer treatment | small molecule | sorafenib | morbilliform | photosensitivity | lapatinib | panitumumab | xerosis | chemotherapy | METASTATIC COLORECTAL-CANCER | mucocutaneous hemorrhage | canertinib | IMATINIB-INDUCED ERYTHRODERMA | bevacizumab | side effects | drug reaction | FOOT SKIN REACTION | sunitinib | papulopustular eruption | cetuximab | imatinib | gefitinib | drug rash | alopecia | EPIDERMAL-GROWTH-FACTOR | dry skin | disturbed wound healing | ADVANCED HEPATOCELLULAR-CARCINOMA | CHRONIC MYELOGENOUS LEUKEMIA | pigment changes | paronychia | stomatitis | dual kinase inhibitors | cutaneous adverse effects | anticancer | ranibizumab | epidermal growth factor receptor inhibitors | DERMATOLOGY | hyperkeratotic hand-foot skin reaction | tyrosine kinase inhibitors | antiangiogenic agents | dermatologic toxicities | drug eruption | multikinase inhibitors | dasatinib | nilotinib | platelet-derived growth factor receptor | adverse sequelae | supportive oncodermatology | targeted therapy | genital rash | FACTOR RECEPTOR INHIBITORS | macular eruption | toxic erythema | erlotinib | pazopanib | CHRONIC MYELOID-LEUKEMIA | EYELASH TRICHOMEGALY SECONDARY | mucositis | vandetanib | vascular endothelial growth factor | PLACEBO-CONTROLLED TRIAL | monoclonal antibodies | Drug Eruptions - etiology | Molecular Targeted Therapy - adverse effects | Humans | Drug Eruptions - therapy | Mucositis - chemically induced | Dose-Response Relationship, Drug | Dermatitis, Photoallergic - etiology | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug Eruptions - diagnosis | Fusion Proteins, bcr-abl - antagonists & inhibitors | Hair Diseases - chemically induced | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Alopecia - chemically induced | Angiogenesis Inhibitors - adverse effects | Cell Membrane - drug effects | Index Medicus
Journal Article
Journal Article
Journal Article
PLoS Pathogens, ISSN 1553-7366, 2014, Volume 10, Issue 6, p. e1004105
  [...]men are up to three times more likely to have onychomycosis than women, though the reasons for this gender difference are not clear [6]. [...]the low... 
TRICHOPHYTON-RUBRUM | TERBINAFINE | THERAPY | DERMATOPHYTOSIS | VIROLOGY | EFFICACY | DRUG-DELIVERY | MICROBIOLOGY | MODEL | PREVALENCE | EPIDEMIOLOGY | PARASITOLOGY | Recurrence | Epidermophyton - physiology | Hand Dermatoses - prevention & control | Prevalence | Age Factors | Humans | Spores, Fungal - growth & development | Hand Dermatoses - drug therapy | Antifungal Agents - therapeutic use | Incidence | Trichophyton - physiology | Microsporum - drug effects | Microsporum - physiology | Disease Reservoirs - microbiology | Foot Dermatoses - epidemiology | Hand Dermatoses - microbiology | Spores, Fungal - drug effects | Onychomycosis - epidemiology | Trichophyton - growth & development | Epidermophyton - growth & development | Trichophyton - drug effects | Onychomycosis - prevention & control | Drug Administration Schedule | Onychomycosis - drug therapy | Administration, Oral | Foot Dermatoses - drug therapy | Microsporum - growth & development | Risk Factors | Foot Dermatoses - microbiology | Spores, Fungal - physiology | Foot Dermatoses - prevention & control | Epidermophyton - drug effects | Hand Dermatoses - epidemiology | Administration, Topical | Antifungal Agents - administration & dosage | Onychomycosis - microbiology | Mycoses | Development and progression | Care and treatment | Health aspects | Risk factors | Onychomycosis | Fungi | Ultrasonic imaging | HIV | Older people | Fingers & toes | Human immunodeficiency virus | Fungal infections | Diabetes | Patients | Foot diseases
Journal Article
Journal Article
BMC Musculoskeletal Disorders, ISSN 1471-2474, 06/2017, Volume 18, Issue 1, pp. 253 - 10
Background: Heightened local inflammation due to muscle trauma or disease is associated with impaired bone regeneration. Methods: We hypothesized that FK506,... 
Composite injury | Open fracture | Orthopaedic trauma | Tacrolimus | Immunomodulation | Adaptive immune response | Inflammation | Volumetric muscle loss | Musculoskeletal | Skeletal muscle injury | DOSE-DEPENDENCE | AXONAL REGENERATION | INDUCTION | MODEL | RHEUMATOLOGY | CYCLOSPORINE-A | IMMUNE-SYSTEM | IMMUNOSUPPRESSION | BONE REGENERATION | ORTHOPEDICS | T-CELLS | Bony Callus - immunology | Bony Callus - drug effects | Torque | Bone Nails | Osteotomy | Humans | Immunosuppressive Agents - therapeutic use | Soft Tissue Injuries - immunology | Rats, Inbred Lew | Soft Tissue Injuries - drug therapy | Male | Bony Callus - pathology | Muscle, Skeletal - injuries | Tibial Fractures - surgery | Tibial Fractures - drug therapy | Fracture Healing - drug effects | Soft Tissue Injuries - complications | Tibial Fractures - physiopathology | T-Lymphocytes - drug effects | Muscle, Skeletal - drug effects | Muscular Diseases - drug therapy | Tacrolimus - pharmacology | Fracture Fixation, Intramedullary - instrumentation | Immunosuppressive Agents - pharmacology | Macrophages - immunology | Disease Models, Animal | Bone Regeneration - drug effects | Immunity, Innate - drug effects | Rats | Muscular Diseases - pathology | Soft Tissue Injuries - pathology | Tacrolimus - therapeutic use | Fracture Fixation, Intramedullary - methods | Muscular Diseases - immunology | Adaptive Immunity - drug effects | Animals | Biopsy | Muscular Diseases - complications | Macrophages - drug effects | T-Lymphocytes - immunology | Muscle, Skeletal - pathology | Complications and side effects | Usage | Muscle weakness | Care and treatment | Bone regeneration | Risk factors | Callus | Cytokines | Mechanical properties | Arthritis | Lymphocytes T | Bone healing | Gene expression | Macrophages | Trauma | Muscle contraction | Skeletal muscle | Regeneration | Bone growth | Fractures | Tibia | Lymphocytes | Stem cells | Laboratory animals | Growth factors
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 08/2017, Volume 11, pp. 2527 - 2535
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2008, Volume 58, Issue 2, pp. 224 - 231
Background Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited. Objective Occurrence of nail... 
Dermatology | 5-FLUOROURACIL | THERAPY | MANAGEMENT | VEHICLE | INVOLVEMENT | DOUBLE-BLIND | INDEX | ARTHRITIS | CYCLOSPORINE | DERMATOLOGY | Nail Diseases - drug therapy | Psoriasis - drug therapy | Infliximab | Humans | Middle Aged | Adult | Antibodies, Monoclonal - therapeutic use | Female | Male | Psoriasis | Drug therapy
Journal Article
16.